Provided by Tiger Trade Technology Pte. Ltd.

ORUKA THERAPEUTICS INC

92.38
+0.73000.80%
Post-market: 92.380.00000.00%16:15 EDT
Volume:585.30K
Turnover:53.98M
Market Cap:6.12B
PE:-45.64
High:94.29
Open:93.40
Low:90.48
Close:91.65
52wk High:115.52
52wk Low:14.67
Shares:66.21M
Float Shares:56.88M
Volume Ratio:0.89
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0242
EPS(LYR):-1.8483
ROE:-18.23%
ROA:-12.95%
PB:5.50
PE(LYR):-49.98

Loading ...

Oruka Therapeutics to Attend Morgan Stanley Global Healthcare Conference

Reuters
·
Sep 10

Oruka Therapeutics CEO Lawrence Klein Sells USD 6.85 Million in Common Shares

Reuters
·
Sep 02

Oruka Therapeutics Files Form 3 for Chief Commercial Officer Larry Todd Edwards

Reuters
·
Aug 26

Oruka Therapeutics Names Todd Edwards Chief Commercial Officer

Reuters
·
Aug 25

Press Release: Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer

Dow Jones
·
Aug 25

Oruka Therapeutics (ORKA) Files $1b Shelf As Investors Weigh A Pricey Valuation

Simply Wall St.
·
Aug 23

Oruka Therapeutics Files $1 Billion Mixed Shelf

MT Newswires Live
·
Aug 22

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 15

Oruka Therapeutics SVP Finance Arjun Agarwal Disposes of 9,999 Common Shares Worth $1,067,833.92

Reuters
·
Aug 15

Oruka Therapeutics (ORKA) Has a New Rating from Wedbush

TIPRANKS
·
Aug 12

Analysts Are Bullish on These Healthcare Stocks: Oruka Therapeutics (ORKA), Zura Bio (ZURA)

TIPRANKS
·
Aug 12

Jefferies Keeps Their Buy Rating on Oruka Therapeutics (ORKA)

TIPRANKS
·
Aug 11

Guggenheim Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)

TIPRANKS
·
Aug 11

Oruka Therapeutics Inc : Leerink Partners Raises Target Price to $179 from $162

THOMSON REUTERS
·
Aug 11

Oruka Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 10

Earnings Flash (ORKA) Oruka Therapeutics Posts Q2 Loss $0.55 a Share, vs. FactSet Est of $0.53 Loss

MT Newswires Live
·
Aug 10

Oruka Therapeutics Inc Q2 Net Income USD -41.206 Million

THOMSON REUTERS
·
Aug 10

Oruka Therapeutics Q2 FY26 Net Loss Widens to $41.2 Million; R&D Expenses Rise to $43.3 Million

Reuters
·
Aug 10

Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 10

Oruka Therapeutics Inc : Leerink Partners Raises Target Price to $162 from $120

THOMSON REUTERS
·
Jul 20